Guidelines for clinical trials of dengue vaccine in endemic areas

Journal of Clinical Virology

Volumn 46, Issue SUPPL. 2, 2009, Pages S7-

  Hombach, Joachim ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Case definition; Efficacy end points; Trial design and location

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; VIRUS ANTIBODY;

ABSENTEEISM; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; DENGUE; DENGUE VIRUS; DISEASE SURVEILLANCE; DRUG EFFICACY; DRUG SAFETY; ENDEMIC DISEASE; FLAVIVIRUS; GEOGRAPHIC DISTRIBUTION; IMMUNOGENICITY; IMMUNOPATHOLOGY; LABORATORY DIAGNOSIS; MEDICAL ETHICS; METHODOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SAMPLE SIZE; SEROCONVERSION; SERODIAGNOSIS; SEROLOGY; SEROTYPE; VIRUS IMMUNITY; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

EID: 70349599840     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(09)70287-2     Document Type: Article

References (18)

1. WHO/IVB/08.12. Guidelines for the clinical evaluation of dengue vaccines in endemic areas. Availalble at http://whqlibdoc.who.int/hq/2008/WHO_IVB_08.12_eng.pdf Accessed 18 November, 2008.
2. Edelman R., and Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas: summary of a World Health Organization Technical Consultation. Vaccine 26 (2008) 4113-4119
3. Nishiura H., and Halstead S.B. Natural history of dengue virus (DENV)-1 and DENV- 4 infections: reanalysis of classic studies. J Infect Dis 195 (2007) 1007-1013
4. Dengue haemorrhagic fever; diagnosis, treatment, prevention and control. 2nd ed. (1997), World Health Organization, Geneva
5. Stephenson J.R. Understanding dengue pathogenesis: implications for vaccine design. Bull World Health Organ 83 (2005) 308-314
6. Rigau-Perez J.G. Severe dengue: the need for new case definitions. Lancet Infect Dis 6 (2006) 297-302
7. Bandyopadhyay S., Lum L.C., and Kroeger A. Classifying dengue: a review of the difficulties in using the WHO case classification for dengue haemorrhagic fever. Trop Med Int Health 11 (2006) 1238-1255
8. Deen J.L., Harris E., Wills B., et al. The WHO dengue classification and case definitions: time for a reassessment. Lancet 368 (2006) 170-173
9. Balmaseda A., Hammond S.N., Perez M.A., et al. Short report: assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am J Trop Med Hyg 73 (2005) 1059-1062
10. Hudgens M.G., Gilbert P.B., and Self S.G. Endpoints in vaccine trials. Stat Methods Med Res 13 (2004) 89-114
11. Vaughn D.W., Green S., Kalayanarooj S., et al. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 176 (1997) 322-330
12. Endy T.P., Chunsuttiwat S., Nisalak A., et al. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am J Epidemiol 156 (2002) 40-51
13. Guidelines for plaque reduction neutralization testing of human antibodies to dengue viruses (2007), World Health Organization, Geneva. (WHO/IVB/07.07) (http://whqlibdoc.who.int/hq/2007/WHO_IVB_07.07_eng.pdf. Accessed 24 Nov2008)
14. WHO Operational guidelines for ethics committees that review biomedical research (2000), World Health Organization, Geneva
15. Emanuel E.J., Wendler D., Killen J., and Grady C. What makes clinical research in developing countries ethical? The benchmarks of ethical research. J Infect Dis 189 (2004) 930-937
16. Guidelines on clinical evaluation of vaccines: regulatory expectations (2004), World Health Organization, Geneva (Annex 1. WHO Technical Report Series, No. 924).
17. ICH harmonized tripartite quideline. Guideline for good clinical practice E6. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (2006). (http://www.ich.org/cache/compo/276-254-1.html, accessed 29 October 2006)
18. Good clinical practice in FDA-regulated clinical trials (2006). (http://www.fda.gov/oc/gcp/default.htm)